![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
, today announced it has wrapped up its presence at the 2025 Consumer Electronics Show (CES) and achieved key strategic milestones. The culmination of the event demonstrates that the company is poised to deliver exceptional value to its customers.
HENDERA
831152
Hengerda New Materials
300946
Fujian Nebula Electronics.,Ltd
300648
4
Cubic Digital Technology
300344
5
HNAC Technology
300490
US Stock MarketDetailed Quotes
ARAY Accuray
- 2.230
- -0.050-2.19%
Close Feb 14 16:00 ET
- 2.300
- +0.070+3.14%
Pre 08:55 ET
229.31MMarket Cap-55.75P/E (TTM)
2.330High2.220Low548.05KVolume2.300Open2.280Pre Close1.24MTurnover0.55%Turnover RatioLossP/E (Static)102.83MShares2.95052wk High4.79P/B221.87MFloat Cap1.40052wk Low--Dividend TTM99.49MShs Float31.090Historical High--Div YieldTTM4.83%Amplitude1.330Historical Low2.254Avg Price1Lot Size
Accuray Stock Forum
Sign in to post a comment
$Accuray (ARAY.US)$
Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance
Positive
Revenue increased 8% YoY to $116.2 million
Turned $9.6M loss into $2.5M profit
Product revenue grew 19% to $61.2 million
Gross profit margin improved to 36.1% from 33.5%
Operating expenses reduced by 7%
Adjusted EBITDA increased to $9.6M from $2.0M
Raised FY2025 guidance
Negative
Service revenue declined 1% to $55.0 million
Gross product orders decreased to $76.8M from $93.9M...
Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance
Positive
Revenue increased 8% YoY to $116.2 million
Turned $9.6M loss into $2.5M profit
Product revenue grew 19% to $61.2 million
Gross profit margin improved to 36.1% from 33.5%
Operating expenses reduced by 7%
Adjusted EBITDA increased to $9.6M from $2.0M
Raised FY2025 guidance
Negative
Service revenue declined 1% to $55.0 million
Gross product orders decreased to $76.8M from $93.9M...
2
$Accuray (ARAY.US)$ Reuters
just
Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the TOMO® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product
just
Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the TOMO® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product
$Accuray (ARAY.US)$
Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product
Thursday, 23rd January at 7:35 am
MADISON, Wis., Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a pro...
Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product
Thursday, 23rd January at 7:35 am
MADISON, Wis., Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a pro...
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
55
19
11
$Accuray (ARAY.US)$
Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System
Monday, 13th January at 3:00 pm
MADISON, Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Adm...
Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System
Monday, 13th January at 3:00 pm
MADISON, Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Adm...
1
4
Scheduled to officially start on January 7, 2025, the Consumer Electronics Show (CES)—a premier tech event that showcases both current products and futuristic concepts from large and small tech firms—once again captured global attention.
At CES 2025, $NVIDIA (NVDA.US)$ is undoubtedly one of the brightest stars on stage. Jensen Huang will personally showcase the company's latest breakthroughs in AI, robotics...
At CES 2025, $NVIDIA (NVDA.US)$ is undoubtedly one of the brightest stars on stage. Jensen Huang will personally showcase the company's latest breakthroughs in AI, robotics...
116
8
193
$Accuray (ARAY.US)$ Accuray's CyberKnife System Offers Promising Outcomes For Brainstem Metastases, Highlighting Safety And Precision
Benzinga· just
Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications
Benzinga· just
Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications
1
No comment yet
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
Blue Jets : I'll follow and see how it goes![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")